78 related articles for article (PubMed ID: 15993933)
1. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.
Barnes MN; Chhieng DF; Dreher M; Jones JL; Grizzle WE; Jones L; Talley L; Partridge EE
Gynecol Oncol; 2005 Sep; 98(3):376-82. PubMed ID: 15993933
[TBL] [Abstract][Full Text] [Related]
2. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
3. [Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism].
Kang HF; Wang XJ; Liu XX; Dai ZJ; Xue FJ; Xue XH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1599-602. PubMed ID: 17121709
[TBL] [Abstract][Full Text] [Related]
4. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
5. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
[TBL] [Abstract][Full Text] [Related]
6. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
Ueno T; Chow LW; Toi M
Biomed Pharmacother; 2006 Jul; 60(6):277-9. PubMed ID: 16806797
[TBL] [Abstract][Full Text] [Related]
7. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of 4-NQO-induced oral carcinogenesis by co-administration of all-trans retinoic acid loaded microspheres and celecoxib.
Park K; Yang JH; Choi Y; Lee C; Kim SY; Byun Y
J Control Release; 2005 May; 104(1):167-79. PubMed ID: 15866343
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
Sinsakul M; Sika M; Rodby R; Middleton J; Shyr Y; Chen H; Han E; Lehrich R; Clyne S; Schulman G; Harris R; Lewis J
Am J Kidney Dis; 2007 Dec; 50(6):946-51. PubMed ID: 18037095
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
Cancer; 2007 Feb; 109(3):588-97. PubMed ID: 17177201
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats.
Márquez-Rosado L; Trejo-Solís MC; García-Cuéllar CM; Villa-Treviño S
J Hepatol; 2005 Oct; 43(4):653-60. PubMed ID: 16023763
[TBL] [Abstract][Full Text] [Related]
15. Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.
De Ruysscher D; Bussink J; Rodrigus P; Kessels A; Dirx M; Houben R; Wanders R
Radiother Oncol; 2007 Jul; 84(1):23-5. PubMed ID: 17532073
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.
Limburg PJ; Wei W; Ahnen DJ; Qiao Y; Hawk ET; Wang G; Giffen CA; Wang G; Roth MJ; Lu N; Korn EL; Ma Y; Caldwell KL; Dong Z; Taylor PR; Dawsey SM
Gastroenterology; 2005 Sep; 129(3):863-73. PubMed ID: 16143126
[TBL] [Abstract][Full Text] [Related]
19. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
[TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia.
Farley JH; Truong V; Goo E; Uyehara C; Belnap C; Larsen WI
Gynecol Oncol; 2006 Nov; 103(2):425-30. PubMed ID: 16677697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
